Consortium analysis of 7 candidate SNPs for ovarian cancer

International Journal of Cancer

Volumn 123, Issue 2, 2008, Pages 380-388

  Ramus, Susan J ^a   Vierkant, Robert A ^b   Johnatty, Sharon E ^c   Pike, Malcolm C ^d   Van Den Berg, David J ^d   Wu, Anna H ^d   Pearce, Celeste Leigh ^d   Menon, Usha ^a   Gentry Maharaj, Aleksandra ^a   Gayther, Simon A ^a   DiCioccio, Richard A ^e   McGuire, Valerie ^f   Whittemore, Alice S ^f   Song, Honglin ^g   Easton, Douglas F ^g   Pharoah, Paul D P ^g   Garcia Closas, Montserrat ^h   Chanock, Stephen ^h   Lissowska, Jolanta ⁱ   Brinton, Louise ^h   Terry, Kathryn L ^j   Cramer, Daniel W ^j   Tworoger, Shelley S ^k   Hankinson, Susan E ^k   Berchuck, Andrew ^l   Moorman, Patricia G ^m   Schildkraut, Joellen M ^m   Cunningham, Julie M ^b   Liebow, Mark ^b   Kjaer, Susanne Kru¨ger ⁿ   Hogdall, Estrid ⁿ   Hogdall, Claus ^o   Blaakaer, Jan ^p   Ness, Roberta B ^q   Moysich, Kirsten B ^e   Edwards, Robert P ^r   Carney, Michael E ^s   Lurie, Galina ^s   Goodman, Marc T ^s   Wang Gohrke, Shan ^t   Kropp, Silke ^u   Chang Claude, Jenny ^u   Webb, P ^v,w   Chen, Xiaoqing ^c   Beesley, Jonathan ^c   Chenevix Trench, Georgia ^c,v,w   Goode, Ellen L ^b,as   Bowtell, D ^c,v   Green, A ^c,v,w   DeFazio, A ^c,v,x   Gertig, D ^c,v,y   Traficante, N ^c,v   Moore, S ^c,v,w   Hung, J ^c,v,x   Fereday, S ^c,v   Harrap, K ^c,v,w   Sadkowsky, T ^c,v,w   Mellon, A ^c,v,z   Robertson, R ^c,v,z   Vanden Bergh, T ^c,v,aa   Maidens, J ^c,v,ab   Nattress, K ^c,v,ac   Chiew, Y E ^c,v,x   Stenlake, A ^c,v,x   Sullivan, H ^c,v,x   Alexander, B ^c,v,w   Ashover, P ^c,v,w   Brown, S ^c,v,w   Corrish, T ^c,v,w   Green, L ^c,v,w   Jackman, L ^c,v,w   Martin, K ^c,v,w   Ranieri, B ^c,v,w   White, J ^c,v,w   Jayde, V ^c,v,ad   Bowes, V L ^c,v   Mamers, P ^c,v,ae   Schmidt, T ^c,v,af   Shirley, H ^c,v,af   Viduka, S ^c,v,af   Tran, H ^c,v,af   Bilic, S ^c,v,af   Glavinas, L ^c,v,af   Proietto, A ^c,v,z   Braye, S ^c,v,z   Otton, G ^c,v,z   Bonaventura, T ^c,v,ag   Stewart, J ^c,v,ag   Friedlander, M ^c,v,ah   Bell, D ^c,v,ab   Baron Hay, S ^c,v,ab   Ferrier, A ^c,v,ab   Gard, G ^c,v,ab   Nevell, D ^c,v,ab   Young, B ^c,v,ab   Camaris, C ^c,v,aa   Crouch, R ^c,v,aa   Edwards, L ^c,v,aa   Hacker, N ^c,v,aa   Marsden, D ^c,v,aa   Robertson, G ^c,v,aa   Beale, P ^c,v,ac   Beith, J ^c,v,ac   Carter, J ^c,v,ac   Dalrymple, C ^c,v,ac   Hamilton, A ^c,v,ac   Houghton, R ^c,v,ac   Russell, P ^c,v,ac   Brand, A ^c,v,x   Jaworski, R ^c,v,x   Harnett, P ^c,v,x   Wain, G ^c,v,x   Crandon, A ^c,v   Cummings, M ^c,v   Horwood, K ^c,v   Obermair, A ^c,v   Wyld, D ^c,v   Nicklin, J ^c,v,ai   Papadimos, D ^c,v,aj   Perrin, L ^c,v,ak   Ward, B ^c,v,ak   Davy, M ^c,v,al   Hall, C ^c,v,al   Dodd, T ^c,v,al   Healy, T ^c,v,al   Pittman, K ^c,v,al   Henderson, D ^c,v,am   Hyde, S ^c,v,am,ap   Miller, J ^c,v,an   Pierdes, J ^c,v,an   Blomfield, P ^c,v,ad   Challis, D ^c,v,ad   McIntosh, R ^c,v,ad   Parker, A ^c,v,ad   Brown, B ^c,v,ao   Rome, R ^c,v,ao   Allen, D ^c,v,ap   Grant, P ^c,v,ap   Laurie, R ^c,v,ap   Robbie, M ^c,v,ap   Healy, D ^c,v,ae   Jobling, T ^c,v,ae   Maniolitas, T ^c,v,ae   McNealage, J ^c,v,ae   Rogers, P ^c,v,ae   Susil, B ^c,v,ae   Veitch, A ^c,v,ae   Constable, J ^c,v,ae   Ping Tong, S ^c,v,ae   Robinson, I ^c,v,ae   Simpson, I ^c,v,ae   Phillips, K ^c,v   Rischin, D ^c,v   Waring, P ^c,v   Loughrey, M ^c,v   O'Callaghan, N ^c,v   Murray, Bill ^c,v   Billson, V ^c,v,aq   Galloway, S ^c,v,aq   Pyman, J ^c,v,aq   Quinn, M ^c,v,aq   Hammond, I ^c,v,ar   McCartney, A ^c,v,ar   Leung, Y ^c,v,ar   Haviv, I ^c,v   Purdie, D ^c,v,w   Whiteman, D ^c,v,w   Zeps, N ^c,v,af   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MAYO CLINIC   (United States)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h NATIONAL CANCER INSTITUTE   (United States)

ⁱ INSTITUTE OF ONCOLOGY   (Poland)

^j BRIGHAM AND WOMEN S HOSPITAL   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

^l DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁿ DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^o UNIVERSITY OF COPENHAGEN   (Denmark)

^p AARHUS UNIVERSITY HOSPITAL   (Denmark)

^q UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^r UNIVERSITY OF PITTSBURGH   (United States)

^s UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^t UNIVERSITY OF ULM   (Germany)

^u GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^v PETER MACCALLUM CANCER CENTRE   (Australia)

^w QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^x WESTMEAD HOSPITAL   (Australia)

^y UNIVERSITY OF MELBOURNE   (Australia)

^z JOHN HUNTER HOSPITAL   (Australia)

^aa Royal Hospital for Women   (Australia)

^ab ROYAL NORTH SHORE HOSPITAL   (Australia)

^ac ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^ad ROYAL HOBART HOSPITAL   (Australia)

^ae MONASH MEDICAL CENTRE   (Australia)

^af Western Australia Research Tissue Network   (Australia)

^ag Newcastle Mater Misericordiae   (Australia)

^ah PRINCE OF WALES HOSPITAL   (Australia)

^ai WESLEY HOSPITAL   (Australia)

^aj SULLIVAN NICOLAIDES PATHOLOGY   (Australia)

^ak Qld   (Australia)

^al ROYAL ADELAIDE HOSPITAL   (Australia)

^am FLINDERS MEDICAL CENTRE   (Australia)

^an QUEEN ELIZABETH HOSPITAL   (Australia)

^ao Epworth Freemasons Hospital   (Australia)

^ap MERCY HOSPITAL FOR WOMEN   (Australia)

^aq ROYAL WOMEN'S HOSPITAL   (Australia)

^ar KING EDWARD MEMORIAL HOSPITAL   (Australia)

^as Mayo Clinic   (United States)

more..

Author keywords

Association study; Neoplasms; Ovarian cancer; Replication; Single nucleotide polymorphism

Indexed keywords

AURORA A KINASE; BRCA2 PROTEIN; CASPASE 8; CYCLIN DEPENDENT KINASE INHIBITOR 2A; RETINOBLASTOMA PROTEIN; STEROID 5ALPHA REDUCTASE 2; TRANSFORMING GROWTH FACTOR BETA1; AURKA PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; CASP8 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; STEROID 5ALPHA REDUCTASE; TUMOR PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; BREAST CANCER; CANCER INVASION; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA FLANKING REGION; FEMALE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENOTYPE; HUMAN; HUMAN TISSUE; INTRON; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; BREAST TUMOR; CARCINOMA; CASE CONTROL STUDY; CLINICAL TRIAL; GENETICS; MULTICENTER STUDY; MUTATION; OVARY TUMOR; RISK;

BRCA2 PROTEIN; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; CASPASE 8; CYCLIN-DEPENDENT KINASE INHIBITOR P16; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; MUTATION; NEOPLASM PROTEINS; ODDS RATIO; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; RETINOBLASTOMA PROTEIN; TESTOSTERONE 5-ALPHA-REDUCTASE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 44949145237     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23448     Document Type: Article

References (43)

1. Antoniou AC, Easton DF. Risk prediction models for familial breast cancer. Future Oncol 2006;2:257-74.
2. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002;31:33-6.
3. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-93.
4. Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, Penegar S, Chandler I, Gorman M, Wood W, Barclay E, Lubbe S, et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 2007;39:984-8.
5. Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM, Prendergast J, Olschwang S, Chiang T, Crowdy E, Ferretti V, Laflamme P, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 2007;39:989-94.
6. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003;361:567-71.
7. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003;33:177-82.
8. Dahlman I, Eaves IA, Kosoy R, Morrison VA, Heward J, Gough SC, Allahabadia A, Franklyn JA, Tuomilehto J, Tuomilehto-Wolf E, Cucca F, Guja C, et al. Parameters for reliable results in genetic association studies in common disease. Nat Genet 2002;30:149-50.
9. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003;361:865-72.
10. Ioannidis JP. Common genetic variants for breast cancer: 32 largely refuted candidates and larger prospects. J Natl Cancer Inst 2006;98:1350-3.
11. Gayther SA, Song H, Ramus SJ, Kjaer SK, Whittemore AS, Quaye L, Tyrer J, Shadforth D, Hogdall E, Hogdall C, Blaeker J, Dicioccio R, et al. Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res 2007;67:3027-35.
12. Dicioccio RA, Song H, Waterfall C, Kimura MT, Nagase H, McGuire V, Hogdall E, Shah MN, Luben RN, Easton DF, Jacobs U, Ponder BA, et al. STK15 polymorphisms and association with risk of invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1589-94.
13. Auranen A, Spurdle AB, Chen X, Lipscombe J, Purdie DM, Hopper JL, Green A, Healey CS, Redman K, Dunning AM, Pharoah PD, Easton DF, et al. BRCA2 Arg372Hispolymorphism and epithelial ovarian cancer risk. Int J Cancer 2003;103:427-30.
14. Healey CS, Dunning AM, Teare MD, Chase D, Parker L, Burn J, Chang-Claude J, Mannermaa A, Kataja V, Huntsman DG, Pharoah PD, Luben RN, et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet 2000;26:362-4.
15. Song H, Ramus SJ, Shadforth D, Quaye L, Kjaer SK, Dicioccio RA, Dunning AM, Hogdall E, Hogdall C, Whittemore AS, McGuire V, Lesueur F, et al. Common variants in RB1 gene and risk of invasive ovarian cancer. Cancer Res 2006;66:10220-6.
16. Lesueur F, Song H, Ahmed S, Luccarini C, Jordan C, Luben R, Easton DF, Dunning AM, Pharoah PD, Ponder BA. Single-nucleotide polymorphisms in the RB1 gene and association with breast cancer in the British population. Br J Cancer 2006;94:1921-6.
17. Beesley J, Jordan SJ, Spurdle AB, Song H, Ramus SJ, Kjaer SK, Hogdall E, DiCioccio RA, McGuire V, Whittemore AS, Gayther SA, Pharoah PD, et al. Association between SNPs in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set. Cancer Epidemiol Biomarkers Prev 2007;16:2557-65.
18. Breast Cancer Association Consortium. Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 2006;98:1382-96.
19. Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, Scollen S, Baynes C, Ponder BA, Chanock S, Lissowska J, Brinton L, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007;39:352-8.
20. Ewart-Toland A, Dai Q, Gao YT, Nagase H, Dunlop MG, Farrington SM, Barnetson RA, Anton-Culver H, Peel D, Ziogas A, Lin D, Miao X, et al. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 2005;26:1368-73.
21. Cheetham GM, Knegtel RM, Coll JT, Renwick SB, Swenson L, Weber P, Lippke JA, Austen DA. Crystal structure of aurora-2, an oncogenic serine/threonine kinase. J Biol Chem 2002;277:42419-22.
22. Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F, MacCarthy-Morrogh L, Ponder BA, Nagase H, Burn J, Ball S, Almeida M, et al. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 2003;34:403-12.
23. Hashiguchi Y, Tsuda H, Yamamoto K, Inoue T, Ishiko O, Ogita S. Combined analysis of p53 and RB pathways in epithelial ovarian can-cer. Hum Pathol 2001;32:988-96.
24. Hashiguchi Y, Tsuda H, Inoue T, Nishimura S, Suzuki T, Kawamura N. Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients. Hum Pathol 2004;35:165-75.
25. Herzog H, Darby K, Hort YJ, Shine J. Intron 17 of the human retinoblastoma susceptibility gene encodes an actively transcribed G protein-coupled receptor gene. Genome Res 1996;6:858-61.
26. Melzer D, Frayling TM, Murray A, Hurst AJ, Harries LW, Song H, Khaw K, Luben R, Surtees PG, Bandinelli SS, Corsi AM, Ferrucci L, et al. A common variant of the p16(INK4a) genetic region is associated with physical function in older people. Mech Ageing Dev 2007;128:370-7.
27. Milde-Langosch K, Ocon E, Becker G, Loning T. p16/MTS1 Inaetivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int J Cancer 1998;79:61-5.
28. Kudoh K, lchikawa Y, Yoshida S, Hirai M, Kikuchi Y, Nagata I, Miwa M, Uchida K. Inaetivation of p16/CDKN2 and p15/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer. Int J Cancer 2002;99:579-82.
29. Goodarzi MO, Azziz R. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab 2006;20:193-205.
30. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996;88:554-9.
31. Makridakis NM, di Salle E, Reichardt JK. Biochemical and pharmacogenetic dissection of human steroid 5 α-reductase type 11. Pharmacogenetics 2000;10:407-13.
32. MacPherson G, Healey CS, Teare MD, Balasubramanian SP, Reed MW, Pharoah PD, Ponder BA, Meuth M, Bhattacharyya NP, Cox A. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 2004;96:1866-9.
33. Frank B, Bermejo JL, Hemminki K, Klaes R, Bugert P, Wappenschmidt B, Schmutzler RK, Burwinkel B. Re: association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 2005;97:1012.
34. Cox A, MacPherson G. Re: association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 2005;97:1012-13.
35. Rosfjord EC, Dickson RB. Growth factors, apoptosis, and survival of mammary epithelial cells. J Mammary Gland Biol Neoplasia 1999;4:229-37.
36. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor β in human disease. N Engl J Med 2000;342:1350-8.
37. Lehmann K, Janda E, Pierreux CE, Rytomaa M, Schulze A, McMahon M, Hill CS, Beug H, Downward J. Raf induces TGFβ production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev 2000;14:2610-22.
38. Dumont N, Arteaga CL. Transforming growth factor-β and breast cancer: tumor promoting effects of transforming growth factor-β. Breast Cancer Res 2000;2:125-32.
39. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Luben RN, Chang-Claude J, Mannermaa A, Kataja V, Pharoah PD, Easton DF, et al. A transforming growth factorβl signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 2003;63:2610-15.
40. Weir BS. Genetic data analysis. 11. Methods for discrete population genetic dataed. Sunderland, MA: Sinauer Associates, 1996.
41. Skol AD, Scott LJ, Abecasis GR, Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 2006;38:209-13.
42. Matzuk MM. Gynecologic diseases get their genes. Nat Med 2005;11:24-6.
43. Fletcher O, Johnson N, Palles C, dos Santos Silva I, McCormack V, Whittaker J, Ashworth A, Peto J. Inconsistent association between the STK15 F31I genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2006;98:1014-18.